Treatment of Acute Myeloid Leukemia
common.study.values.description
“Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia”
This study will evaluate the efficacy of uproleselan (GMI-1271), a specific E-selectin antagonist, in combination with chemotherapy to treat relapsed/refractory AML, compared to chemotherapy alone. The safety of uproleselan when given with chemotherapy will also be investigated in patients with relapsed/refractory AML
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-yes
Drug - Uproleselan
A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin
Drug - Placebo
Saline, 0.9% Sodium Chloride
participant.views.study.view.additional
participant.views.study.view.scientific-title
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
common.study.values.clinical-trial-id
NCT03616470
participant.views.study.view.id
bo2YBa
